Literature DB >> 25408621

Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

Krishnayan Haldar1, Kezia Gaitskell2, Andrew Bryant3, Heather O Dickinson3, Shibani Nicum4, Sean Kehoe1, Jo Morrison5.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness and harmful effects of interventions, which target the epidermal growth factor receptor, in the treatment of ovarian cancer.

Entities:  

Year:  2009        PMID： 25408621      PMCID： PMC4233122          DOI： 10.1002/14651858.CD007927.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN： 1361-6137


  26 in total

1.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

Authors:  J Engel; R Eckel; G Schubert-Fritschle; J Kerr; W Kuhn; J Diebold; R Kimmig; J Rehbock; D Hölzel
Journal:  Eur J Cancer       Date:  2002-12       Impact factor: 9.162

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

4.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

5.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

Authors:  A J Ekstrand; N Sugawa; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

7.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.

Authors:  A N Gordon; N Finkler; R P Edwards; A A Garcia; M Crozier; D H Irwin; E Barrett
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

8.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

Review 9.  Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Authors:  J Morrison; A Swanton; S Collins; S Kehoe
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

10.  The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

Authors:  J M Bartlett; S P Langdon; B J Simpson; M Stewart; D Katsaros; P Sismondi; S Love; W N Scott; A R Williams; A M Lessells; K G Macleod; J F Smyth; W R Miller
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640
View more
  1 in total

1.  Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

Authors:  Jo Morrison; Clemens Thoma; Richard J Goodall; Thomas J Lyons; Kezia Gaitskell; Alison J Wiggans; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2018-10-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.